Results 211 to 220 of about 28,326 (256)
Correction: Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study. [PDF]
Front ImmunolZhang X +6 more
europepmc +1 more source
Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study. [PDF]
JMIR Res ProtocMichalski K +13 more
europepmc +1 more source
Role of ctDNA in Breast Cancer [PDF]
Cancers, 2022 Breast cancer is currently classified by immunohistochemistry. However, technological advances in the detection of circulating tumor DNA (ctDNA) have made new options available for diagnosis, classification, biological knowledge, and treatment selection.
Enriqueta Felip +2 more
exaly +9 more sources
The Role of ctDNA in Gastric Cancer
Cancers, 2022 Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and ...
Susanna Slater +2 more
exaly +5 more sources
ctDNA as a cancer biomarker: A broad overview
Critical Reviews in Oncology/Hematology, 2020 Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of treatment, and prognosis: the so-called liquid biopsy. Liquid biopsy is a minimally invasive approach and presents the sum of ctDNA from primary and secondary tumor sites. It has been
Valeria Pereira Ferrer
exaly +4 more sources
Liquid Biopsy, ctDNA Diagnosis through NGS
Life, 2021 Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains ...
Rongqin Ke, Chi-Meng Tzeng
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Chasing ctDNA in Patients With Sarcoma
American Society of Clinical Oncology Educational Book, 2020Liquid biopsies are new technologies that allow cancer profiling of tumor fragments found in body fluids, such as peripheral blood, collected noninvasively from patients with malignancies. These assays are increasingly valuable in clinical oncology practice as prognostic biomarkers, as guides for therapy selection, for treatment monitoring, and for ...
Catherine C, Coombs +2 more
openaire +2 more sources
Methods for Measuring ctDNA in Lymphomas
2018Plasma cell-free DNA (cfDNA) is an easily accessible source of tumor DNA that allows accurate profiling of lymphoma patients, representing a complementary source of tumor DNA to tissue biopsy for genotyping. Applications of cfDNA analysis in lymphomas include: (1) identification of tumor mutations in a biopsy-free manner; (2) tracking tumor clonal ...
Rossi, Davide +3 more
openaire +4 more sources